Trial of a New Formulation of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease
A 6-Week Feasibility Trial of a New Formulation of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD)
Sponsor: Keryx Biopharmaceuticals
A observational or N/A phase clinical study on End-stage Renal Disease and Hyperphosphatemia, this trial is completed. The trial is conducted by Keryx Biopharmaceuticals and has accumulated 9 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2023 — Jul 2024 [monthly]
Completed
-
Dec 2022 — Jan 2023 [monthly]
Completed
▶ Show 4 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Completed
-
Jun 2018 — Jan 2021 [monthly]
Completed
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: PHASE2 → None
-
Jan 2017 — Apr 2018 [monthly]
Completed PHASE2
First recorded
Jan 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Keryx Biopharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .